Whan In Pharm signs exclusive agreement of introducing the epilepsy treatment ‘Zebinix’

Published: 2018-02-28 17:04:23

Updated: 2018-02-28 17:04:23

Whan In Pharm(CEO Won-Bum Lee) signed an exclusive license agreement of ‘Zebinix,’ an epilepsy treatment developed by Portuguese Bial(CEO António Portela), in Korea at the headquarters on the 26^th.

‘Zebinix,’ a once-daily new drug, is a product that is being sold in the U.S.( Aptiom®) and Europe(Zebinix®).

The main substance ‘Eslicarbazepine Acetate’ is being used as not only a single therapy...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.